[{"label": "0", "tokenized": "the food and drug administr on wednesday approv power combin of two antivir drug to treat chronic hepat , liver infect that can lead to cirrhosi , liver cancer and liver failur", "origin": "The Food and Drug Administration on Wednesday approved a powerful combination of two antiviral drugs to treat chronic hepatitis C, a liver infection that can lead to cirrhosis, liver cancer and liver failure"}, {"label": "0", "tokenized": "four million american are estim to have chronic hepat , and 10,000 die from it each year", "origin": "Four million Americans are estimated to have chronic hepatitis C, and 10,000 die from it each year"}, {"label": "0", "tokenized": "the diseas is the lead reason for liver transplant", "origin": "The disease is the leading reason for liver transplantation"}, {"label": "0", "tokenized": "the newli approv treatment , known as rebetron , work far better than sole standard treatment", "origin": "The newly approved treatment, known as Rebetron, works far better than sole standard treatment"}, {"label": "0", "tokenized": "but it is expens , it pose seriou side effect and work in onli about half the patient who take it", "origin": "But it is expensive, it poses serious side effects and works in only about half the patients who take it"}, {"label": "0", "tokenized": "although it can erad sign of infect , it can not be call cure", "origin": "Although it can eradicate signs of infection, it cannot be called a cure"}, {"label": "0", "tokenized": "and doctor say that not everyon with hepat need it", "origin": "And doctors say that not everyone with hepatitis C needs it"}, {"label": "0", "tokenized": "the treatment consist of six month cours of interferon inject and ribavirin capsul", "origin": "The treatment consists of a six month course of interferon injections and ribavirin capsules"}, {"label": "0", "tokenized": "the full cours of therapi will cost 6,400 to 8,600 , depend on how high dose patient need", "origin": "The full course of therapy will cost $6,400 to $8,600, depending on how high a dose a patient needs"}, {"label": "0", "tokenized": "rebetron , which is made by schere plough corp of madison , nj , ha been approv for use onli in peopl who relaps after the standard treatment for hepat , which is cours of interferon inject", "origin": "Rebetron, which is made by Schering Plough Corp of Madison, NJ, has been approved for use only in people who relapse after the standard treatment for hepatitis C, which is a course of interferon injections"}, {"label": "0", "tokenized": "that therapi elimin the diseas in onli 10 percent to 20 percent of patient", "origin": "That therapy eliminates the disease in only 10 percent to 20 percent of patients"}, {"label": "1", "tokenized": "about half do not respond to interferon at all", "origin": "About half do not respond to interferon at all"}, {"label": "1", "tokenized": "the remain 30 percent to 40 percent respond to interferon and then relaps , and those are the patient for whom rebetron ha been approv", "origin": "The remaining 30 percent to 40 percent respond to interferon and then relapse, and those are the patients for whom Rebetron has been approved"}, {"label": "0", "tokenized": "test in such group , rebetron reduc the viru to undetect level in 45 percent , an effect that persist when the patient were test again six month after treatment end", "origin": "Tested in such a group, Rebetron reduced the virus to undetectable levels in 45 percent, an effect that persisted when the patients were tested again six months after treatment ended"}, {"label": "0", "tokenized": "in patient given interferon alon , onli 5 percent had undetect level", "origin": "In patients given interferon alone, only 5 percent had undetectable levels"}, {"label": "0", "tokenized": "annot ( stori can end here", "origin": "ANNOTATION (STORY CAN END HERE"}, {"label": "0", "tokenized": "option materi follow ) /annot dr leonard seeff , senior scientist for hepat research at the nation institut of diabet and digest and kidney diseas , who wa not involv in the studi , said those result meant there wa good chanc that the effect would last", "origin": "OPTIONAL MATERIAL FOLLOWS) /ANNOTATION Dr Leonard Seeff, a senior scientist for hepatitis C research at the National Institute of Diabetes and Digestive and Kidney Diseases, who was not involved in the study, said those results meant there was a good chance that the effects would last"}, {"label": "0", "tokenized": "in studi of patient who respond to interferon alon , he said , those who were free of the viru at six month remain so at six year", "origin": "In studies of patients who responded to interferon alone, he said, those who were free of the virus at six months remained so at six years"}, {"label": "0", "tokenized": "`` but 'm not sure we wo n't find peopl with recur diseas as we go further out , '' seeff said", "origin": "\"But I'm not sure we won't find people with recurring disease as we go further out,\" Seeff said"}, {"label": "0", "tokenized": "`` we need much longer time to follow all these peopl", "origin": "\"We need a much longer time to follow all these people"}, {"label": "0", "tokenized": "the proof will come 20 year from now ''", "origin": "The proof will come 20 years from now\""}, {"label": "0", "tokenized": "even though rebetron ha been approv onli for patient who have relaps after tri interferon , doctor will be free to prescrib it as they see fit", "origin": "Even though Rebetron has been approved only for patients who have relapsed after trying interferon, doctors will be free to prescribe it as they see fit"}, {"label": "0", "tokenized": "seeff and dr jay hoofnagl , director of the divis of digest diseas and nutrit at the nation institut said they expect that mani doctor would prescrib it for all hepat patient , includ those who have not taken interferon or who did not respond to it", "origin": "Seeff and Dr Jay Hoofnagle, director of the division of digestive diseases and nutrition at the national institute said they expected that many doctors would prescribe it for all hepatitis C patients, including those who have not taken interferon or who did not respond to it"}, {"label": "0", "tokenized": "hoofnagl said data had been present at medic meet show that when the combin wa given for one year to peopl who had never been treat befor , the relaps rate wa onli 20 percent", "origin": "Hoofnagle said data had been presented at medical meetings showing that when the combination was given for one year to people who had never been treated before, the relapse rate was only 20 percent"}, {"label": "0", "tokenized": "given the poor respons rate with interferon alon , he said , it seem reason to go straight to the combin", "origin": "Given the poor response rate with interferon alone, he said, it seems reasonable to go straight to the combination"}, {"label": "0", "tokenized": "but the drug can have seriou side effect", "origin": "But the drugs can have serious side effects"}, {"label": "0", "tokenized": "while interferon alon is associ with flulik side effect , ribavirin can caus sever anemia that come on suddenli , hoofnagl said , and in peopl with cardiovascular diseas that can touch off heart attack or stroke", "origin": "While interferon alone is associated with flulike side effects, ribavirin can cause severe anemia that comes on suddenly, Hoofnagle said, and in people with cardiovascular disease that can touch off a heart attack or stroke"}, {"label": "0", "tokenized": "it can also caus birth defect , so women must avoid pregnanc while they take it and for six month after", "origin": "It can also cause birth defects, so women must avoid pregnancy while they take it and for six months after"}, {"label": "0", "tokenized": "psychiatr problem have also been report", "origin": "Psychiatric problems have also been reported"}, {"label": "0", "tokenized": "in addit , the interferon compon of the treatment caus flulik symptom", "origin": "In addition, the interferon component of the treatment causes flulike symptoms"}, {"label": "0", "tokenized": "becaus of the risk of treatment , and it partial success rate , hoofnagl said , doctor have tri to determin which patient truli need it rather than just give the drug to everyon with hepat onli 20 percent to 30 percent of peopl with chronic infect develop cirrhosi , liver failur or cancer", "origin": "Because of the risks of treatment, and its partial success rate, Hoofnagle said, doctors have tried to determine which patients truly need it rather than just giving the drugs to everyone with hepatitis C Only 20 percent to 30 percent of people with chronic infections develop cirrhosis, liver failure or cancer"}, {"label": "0", "tokenized": "it is imposs to predict just which one will becom sever ill , but medic author now recommend treatment onli for patient who have detect viral level and abnorm result on test of liver enzym", "origin": "It is impossible to predict just which ones will become severely ill, but medical authorities now recommend treatment only for patients who have detectable viral levels and abnormal results on tests of liver enzymes"}, {"label": "0", "tokenized": "other can be monitor and treat later if the diseas seem to be progress", "origin": "Others can be monitored and treated later if the disease seems to be progressing"}, {"label": "0", "tokenized": "`` if it 's mild , say let 's follow it care and wait it out until we have littl bit better therapi , '' hoofnagl said", "origin": "\"If it's mild, I say let's follow it carefully and wait it out until we have a little bit better therapy,\" Hoofnagle said"}, {"label": "0", "tokenized": "`` some peopl do n't want to be treat at all , but other are so anxiou that they do n't care what you tell them and they just want to be treat ''", "origin": "\"Some people don't want to be treated at all, but others are so anxious that they don't care what you tell them and they just want to be treated\""}]